Physician profile
Bryan Garcia
NPI 1700146685
$28,970.48
in general payments reported to CMS, 2019-2025
13 companies · $5,304 in 2025
The $5,304 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $150 · 2021: $2,615 · 2022: $2,672 · 2023: $15K · 2024: $3,173 · 2025: $5,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Travel and Lodging: $1,237 · Food and Beverage: $678 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,836.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Travel and Lodging | $1,236.70 |
| Food and Beverage | $678.45 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $17,399.68 | 2019-2025 | Arikayce |
| Mannkind Corporation | $5,060.00 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $3,150.00 | 2023 | |
| Mylan Specialty L.P. | $2,637.29 | 2021-2022 | |
| Electromed, INC. | $397.27 | 2019-2024 | Smartvest |
| Viatris Specialty LLC | $121.82 | 2025 | Tobi Podhaler |
| Abbvie INC. | $73.94 | 2022 | |
| Glaxosmithkline, LLC. | $49.58 | 2023-2024 | Arexvy, Brexafemme |
| Novartis Pharmaceuticals Corporation | $31.39 | 2024 | |
| Genentech USA, INC. | $29.87 | 2022 | |
| Dexcom, INC. | $19.64 | 2023 | Dexcom G6 Transmitter |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.